Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 60

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 60
---
       in column (a)) 
                  (c) |
| Equity compensation plans approved by security holders:    |     |                  |     |                     |     |                      |
| 2011 and 2016 plans                                        |     |       14,951,687 |     |            $3.41(1) |     |        16,674,175(2) |
| Equity compensation plans not approved by security holders |     |       500,000(3) |     |                2.26 |     |                    — |
| Total                                                      |     |       15,451,687 |     |               $3.37 |     |           16,674,175 |

| (1) | Options granted under the 2011 Plan up to March 3, 2015 have a Canadian dollar denominated exercise price. Options granted under the 2011 Plan after March 3, 2015 have a US dollar denominated exercise price. For options with exercise prices denominated in Canadian dollars, in order to calculate a weighted-average exercise price for the purpose of the table, exercise prices have been converted to US dollars using the December 31, 2024 Reuters closing exchange rate of 0.695. |

| (2) | The 2016 Plan and 2011 Plan had 16,674,175 shares and 0 shares, respectively, available for future issuance as of December 31, 2024. |

| (3) | Represents a grant of a stock option to Mr. Naftzger made outside the 2016 Plan or any other equity incentive plan as an inducement material to Mr. Naftzger’s entering into employment with us pursuant to Nasdaq Stock Market LLC Listing Rule 5635(c)(4). |

39

TABLE OF CONTENTS

RELATED PARTY TRANSACTIONS Related Party Transactions Policy Our Board has a written policy for reviewing and approving transactions between us and our related persons, including directors, director nominees, executive officers, 5% Shareholders and their immediate family members and affiliates. In determining whether to authorize, approve and/or ratify a related party transaction, our Audit Committee may use any process and review any information that it determines is reasonable in light of the circumstances in order to determine if such transaction is fair and reasonable and on terms no less favorable to us than could be obtained in a comparable arm’s length transaction with an unrelated third party. All of the transactions described below under “Certain Relationships and Related Party